Back to top

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's ...

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate | VALN Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Valneva SE Sponsored ADR (VALN)